California, USA-based biotech TRex Bio (NYSE: TREX) closed up 1.7% at $46.71 yesterday, after it announced a multi-year research collaboration and exclusive worldwide license agreement with US pharma major Eli Lilly (NYSE: LLY) to develop novel therapies for the treatment of immune-mediated diseases.
This agreement builds on a previous collaboration with Lilly. The deal also adds to TRex Bio’s a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica, a part of US healthcare giant Johnson & Johnson (NYSE: JNJ), signed early last year, in exchange for an undisclosed upfront payment, option fees, milestones and royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze